The Performance of Multi-tracer Multimodality PET in Lymphoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- SUVmax
Study Overview
Brief Summary
Investigating the performance of Multi-tracer Multimodality PET in lymphoma
Detailed Description
In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 15 Years to 80 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •pathologically diagnosed as lymphoma;
- •Written informed consent for receiving FAPI-04 PET examinations.
- •cancer planned chemotherapy or immunotherapy scheme.
- •expected survival ≥ 12 weeks
Exclusion Criteria
- •cannot lie supine for half an hour;
- •refuse to join the clinical researcher;
- •severe liver or kidney dysfunction
- •pregnancy or lactation
Outcomes
Primary Outcomes
SUVmax
Time Frame: 150 days
Standardized uptake value of 68Ga/ 18F-NOTA-FAPI 04 for target lesion of subject or suspected tumor in each time point window (SUV)
Secondary Outcomes
No secondary outcomes reported
Investigators
Xuejuan Wang
Principal Investigator
Peking University Cancer Hospital & Institute